Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
• Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
• Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
• Confirmed cancer-free survivorship confirmed at the time of study inclusion.
Locations
United States
California
City of Hope Medical Center
RECRUITING
Monrovia
Other Locations
China
Second Affiliated Hospital of Dalian Medical University
RECRUITING
Dalian
Spain
Barcelona University
RECRUITING
Barcelona
La Paz University Hospital
RECRUITING
Madrid
Contact Information
Primary
Ajay Goel, PhD
AJGOEL@COH.ORG
6262183452
Time Frame
Start Date: 2023-03-15
Estimated Completion Date: 2026-06-18
Participants
Target number of participants: 400
Treatments
Stage II/III Colorectal Cancer, with Recurrence (Training)
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.
Stage II/III Colorectal Cancer, without Recurrence (Training)
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
Stage II/III Colorectal Cancer, with Recurrence (Validation)
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.
Stage II/III Colorectal Cancer, without Recurrence (Validation)
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
Related Therapeutic Areas
Sponsors
Leads: City of Hope Medical Center